Targeting the BMK1 MAP kinase pathway in cancer therapy

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3527-3532

  Yang, Qingkai ^a   Lee, Jiing Dwan ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BIX 02188; BIX 02189; INDOLINONE 6 CARBOXAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; XMD 8 92;

BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LUNG TUMOR; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; UPREGULATION; UTERINE CERVIX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; CELL CYCLE; HUMANS; MAP KINASE KINASE 5; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 7; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79957920759     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2504     Document Type: Review

References (62)

1. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40. (Pubitemid 32225829)
2. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
3. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007;26:3100-12. (Pubitemid 46763006)
4. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 1995;213:715-24.
5. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem 1995;270:12665-9.
6. Chao TH, Hayashi M, Tapping RI, Kato Y, Lee JD. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J Biol Chem 1999;274:36035-8.
7. Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, et al. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. J Biol Chem 2001;276:5093-100.
8. Blank JL, Gerwins P, Elliott EM, Sather S, Johnson GL. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J Biol Chem 1996;271:5361-8.
9. Garcia L, Garcia F, Llorens F, Unzeta M, Itarte E, Gómez N. PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress. FEBS Lett 2002;523:90-4. (Pubitemid 34786064)
10. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 2006;7:782-6. (Pubitemid 44275395)
11. Kondoh K, Terasawa K, Morimoto H, Nishida E. Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. Mol Cell Biol 2006;26:1679-90.
12. Borges J, Pandiella A, Esparís-Ogando A. Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal 2007;19:1473-87. (Pubitemid 46818913)
13. Kasler HG, Victoria J, Duramad O, Winoto A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol 2000;20:8382-9.
14. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998;395:713-6. (Pubitemid 28475970)
15. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007;67:4199-209. (Pubitemid 46815066)
16. Hayashi Y, Iwashita T, Murakamai H, Kato Y, Kawai K, Kurokawa K, et al. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation. Biochem Biophys Res Commun 2001;281:682-9. (Pubitemid 32917855)
17. Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002;22:270-85. (Pubitemid 33144274)
18. English JM, Pearson G, Baer R, Cobb MH. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 1998;273:3854-60. (Pubitemid 28103240)
19. Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 1999;274:26563-71.
20. English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, Cobb MH. Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 1999;274:31588-92.
21. Abe J, Takahashi M, Ishida M, Lee JD, Berk BC. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J Biol Chem 1997;272:20389-94. (Pubitemid 27355589)
22. Sun W, Wei X, Kesavan K, Garrington TP, Fan R, Mei J, et al. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Mol Cell Biol 2003;23:2298-308. (Pubitemid 36351013)
23. Scapoli L, Ramos-Nino ME, Martinelli M, Mossman BT. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene 2004;23:805-13. (Pubitemid 38241281)
24. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene 2007;26:7313-23. (Pubitemid 350115977)
25. Song H, Jin X, Lin J. Stat3 upregulates MEK5 expression in human breast cancer cells. Oncogene 2004;23:8301-9. (Pubitemid 39531841)
26. Marchetti A, Colletti M, Cozzolino AM, Steindler C, Lunadei M, Mancone C, et al. ERK5/MAPK is activated by TGFbeta in hepatocytes and required for the GSK-3beta-mediated Snail protein stabilization. Cell Signal 2008;20:2113-8.
27. Yan C, Takahashi M, Okuda M, Lee JD, Berk BC. Fluid shear stress stimulates big mitogen-activated protein kinase 1 (BMK1) activity in endothelial cells. Dependence on tyrosine kinases and intracellular calcium. J Biol Chem 1999;274:143-50. (Pubitemid 29035041)
28. Rovida E, Spinelli E, Sdelci S, Barbetti V, Morandi A, Giuntoli S, et al. ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J Immunol 2008;180:4166-72.
29. Suzaki Y, Yoshizumi M, Kagami S, Koyama AH, Taketani Y, Houchi H, et al. Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J Biol Chem 2002;277:9614-21. (Pubitemid 34953051)
30. Sticht C, Freier K, Knöpfle K, Flechtenmacher C, Pungs S, Hofele C, et al. Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia 2008;10:462-70. (Pubitemid 351657388)
31. Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, et al. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 2007;109:3015-23. (Pubitemid 46482102)
32. Garaude J, Cherni S, Kaminski S, Delepine E, Chable-Bessia C, Benkirane M, et al. ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol 2006;177:7607-17. (Pubitemid 44846275)
33. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, et al. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 2008;38:209-17. (Pubitemid 351162843)
34. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003;22:1381-9. (Pubitemid 36384600)
35. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002;132:293-301. (Pubitemid 35024776)
36. Hayashi M, Tapping RI, Chao TH, Lo JF, King CC, Yang Y, et al. BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem 2001;276:8631-4.
37. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010;18:258-67.
38. Zen K, Yasui K, Nakajima T, Zen Y, Zen K, Gen Y, et al. ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer 2009;48:109-20.
39. Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, Wang CY, et al. Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 2007;177:253-64. (Pubitemid 46658637)
40. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 2005;65:7699-706. (Pubitemid 41297244)
41. Roberts OL, Holmes K, Müller J, Cross DA, Cross MJ. ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells. J Cell Sci 2010;123:3189-200.
42. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, et al. A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. Blood 2009;114:4592-600.
43. Bos JL. Linking Rap to cell adhesion. Curr Opin Cell Biol 2005;17:123-8. (Pubitemid 40380934)
44. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006;31:680-6. (Pubitemid 44791945)
45. Sawhney RS, Liu W, Brattain MG. A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 2009;219:152-61.
46. Schramp M, Ying O, Kim TY, Martin GS. ERK5 promotes Src-induced podosome formation by limiting Rho activation. J Cell Biol 2008;181:1195-210. (Pubitemid 351915492)
47. Castro NE, Lange CA. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res 2010;12:R60.
48. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997;16:7054-66. (Pubitemid 27520805)
49. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, et al. Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 2004;113:1138-48. (Pubitemid 38544099)
50. Kato Y, Zhao M, Morikawa A, Sugiyama T, Chakravortty D, Koide N, et al. Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J Biol Chem 2000;275:18534-40. (Pubitemid 30414815)
51. Marinissen MJ, Chiariello M, Pallante M, Gutkind JS. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol Cell Biol 1999;19:4289-301. (Pubitemid 29242004)
52. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A. Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. Nature 1991;354:531-4.
53. Price MA, Rogers AE, Treisman R. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J 1995;14:2589-601.
54. Young MR, Colburn NH. Fra-1 a target for cancer prevention or intervention. Gene 2006;379:1-11. (Pubitemid 44247331)
55. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene 2005;24:7310-9. (Pubitemid 41622235)
56. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 2010;10:384-91.
57. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10:775-83.
58. Tatake RJ, O'Neill MM, Kennedy CA, Wayne AL, Jakes S, Wu D, et al. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun 2008;377:120-5.
59. Flaherty PT, Chopra I, Jain P, Yi S, Allen E, Cavanaugh J. Identification of benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway. Bioorg Med Chem Lett 2010;20:2892-6.
60. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001;502:21-4. (Pubitemid 32722053)
61. Iñesta-Vaquera FA, Campbell DG, Tournier C, Gómez N, Lizcano JM, Cuenda A. Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 2010;22:1829-37.
62. Hayashi M, Lee JD. Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice. J Mol Med 2004;82:800-8.